- Home
- News
- latamerica
- vascular application
Vascular Application Articles & Analysis
14 news found
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. ...
With advances made within the past ten years, the research community gained a better understanding of the potential for surface chemistry in areas including heterogeneous catalysis, semiconductors, medicine, anticorrosion, lubrication, and nanotechnology,” said one of the senior scientists from Alfa Chemistry. While countless applications are still being explored, ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
(OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for shockwave systems in the non-medical field, announced today the patent activity for the full year 2020 and the first quarter of ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. ...
(SNWV) focuses on the development and commercialization of innovative advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications of shockwave and ultrasound systems in the non-medical field, announced today the patent activity for the past year. ...
This technological advancement supports clinical research in the evaluation of anomalies in several applications, including dermatology, neurology, vascular, and MSK. “UHF ultrasound, delivered through FUJIFILM VisualSonics’ systems, is the highest resolution medical ultrasound available today. ...
(OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field today presented results from a clinical case series that demonstrated improved wound healing when treated with its ...
Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary polymers, activation technologies, and delivery devices, with applications in multiple therapeutic areas. TISSIUM’s ...
ByTISSIUM
Corindus, a Siemens Healthineers company and leading developer of precision vascular robotics, announced today that Circulation: Cardiovascular Interventions has published clinical results from a comparative study between robotic percutaneous coronary intervention (PCI) and manual PCI. ...
Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced that it received a $3 million Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health to use its EchoMark & EchoSure devices to support arteriovenous (AV) fistula maturation and long-term viability. The award provides capital for prospective clinical ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) ...